Prognostic value of nodal ratios in node-positive breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2910-2916

  Woodward, Wendy A ^a   Vinh Hung, Vincent ^b   Ueno, Naoto T ^b   Yee, Chung Cheng ^b   Royce, Melanie ^b   Tai, Patricia ^b   Vlastos, Georges ^b   Wallace, Anne Marie ^b   Hortobagyi, Gabriel N ^b   Nieto, Yago ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DATA BASE; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; BREAST TUMOR; MORTALITY; PATHOLOGY;

BREAST NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS;

EID: 33745539386     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.1526     Document Type: Review

References (42)

1. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002
2. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
3. Woodward WA, Strom EA, Tucker SL, et al: Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244-3248, 2003
4. Sinn HP, Habedank ACC, von Fournier D, et al: Reclassification of stages leads to changes of relative survival rates: The new TNM classification for breast cancer. Geburtshilfe und Frauenheilkunde 64:962-967, 2004
5. Bolufer P, Molina R, Ruiz A, et al: Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clin Chim Acta 229:107-122, 1994
6. Walker MJ, Osborne MD, Young DC, et al: The natural history of breast cancer with more than 10 positive nodes. Am J Surg 169:575-579, 1995
7. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
8. Tsuchiya A, Kanno M, Abe R: The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today 27:902-906, 1997
9. Nieto Y, Cagnoni PJ, Shpall EJ, et al: A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res 5:3425-3431, 1999
10. Katz A, Buchholz TA, Thames H, et al: Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: Implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys 50:397-403, 2001
11. Bolwell B, Andresen S, Pohlman B, et al: Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer. Bone Marrow Transplant 27:843-646, 2001
12. Schneeweiss A, Goerner R, Hensel MA, et al: Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transplant 7:332-342, 2001
13. Knoop AS, Bentzen SM, Nielsen MM, et al: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376-3384, 2001
14. Schmoor C, Sauerbrei W, Bastert G, et al: Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer 37:1123-1131, 2001
15. Hensel M, Schneeweiss A, Sinn HP, et al: P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 100:290-296, 2002
16. van der Wal BC, Butzelaar RM, van der Meij S, et al: Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 28:481-489, 2002
17. Nieto Y, Nawaz S, Jones RB, et al: Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20:707-718, 2002
18. Jafarimojarred E, Jahanzad I, Tirgari F, et al: Immunohistochemistry versus histopathology in breast cancer. Int J Cancer 100:208, 2002
19. Grills IS, Kestin LL, Goldstein N, et al: Risk factors for regional nodal failure after breast-conserving therapy: Regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys 56:658-670, 2003
20. Megale Costa LJ, Soares HP, Gaspar HA, et al: Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 27:304-306, 2004
21. Gurkaynay M, Yildiz F, Atahan L: T3N0M0 Breast cancer patients: A subgroup with favorable prognosis. Turkish Journal of Cancer 33:144-149, 2003
22. Voordeckers M, Vinh-Hung V, Van de Steene J, et al: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 70: 225-230, 2004
23. Cheng YC, Rondon G, Yang Y, et al: The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10:794-804, 2004
24. Truong PT, Berthelet E, Lee J, et al: Prognostic significance of the percentage of positive/dissected axillary nodes in breast cancer relapse and survival in patients with 1-3 positive axillary nodes. Cancer 103:2006-2014, 2005
25. Smith BD, Smith GL, Haffty BG: Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer. J Clin Oncol 23:1409-1419, 2005
26. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
27. Silberman AW, Sarna GP, Palmer D: Adjuvant radiation trials for high-risk breast cancer patients: Adequacy of lymphadenectomy. Ann Surg Oncol 7:357-360, 2000
28. Coates A: Management of early breast cancer: An Australian consensus report. Clinical Oncological Society of Australia, the Australian-New Zealand Breast Cancer Trials Group, the Medical Oncology Group of Australia and the Breast Section, Royal Australasian College of Surgeons. Oncology 52:82-85, 1995
29. NIH consensus conference: Treatment of early-stage breast cancer. JAMA 265:391-395, 1991
30. Axillary dissection: The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer - Canadian Association of Radiation Oncologists. CMAJ 158:S22-S26, 1998 (suppl 3)
31. Somner JE, Dixon JM, Thomas JS: Node retrieval in axillary lymph node dissections: Recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 57:845-848, 2004
32. Schaapveld M, Otter R, de Vries EG, et al: Variability in axillary lymph node dissection for breast cancer. J Surg Oncol 87:4-12, 2004
33. Graversen HP, Blichert-Toft M, Andersen JA, et al: Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 14:407-412, 1988
34. Fowble B, Solin LJ, Schultz DJ, et al: Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 17:703-710, 1989
35. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772, 1981
36. Vinh-Hung V, Verschraegen C, Promish DI, et al: Ratios of involved nodes in early breast cancer. Breast Cancer Res 6:R680-R688, 2004
37. Fletcher G, Montague E, Tapley N, et al: Radiotherapy in the management of nondisseminated breast cancer, in Textbook of Radiotherapy. Philadelphia, PA, Lea and Febiger, 1980, pp 573
38. Menes TS, Tartter PI, Mizrachi H, et al: Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg 200:323-327, 2005
39. Martinez-Trufero J, Artal-Cortes A, Zorrilla M, et al: New distinctive features on the study of prognostic factors in patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NAC). Proc Am Soc Clin Oncol 20, 2001 (abstr 3069)
40. Germain I, Fortin A, Dagnault A, et al: The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer. Proc Am Soc Clin Oncol 23, 2004 (abstr 611)
41. Cserni G, Burzykowski T, Vinh-Hung V, et al: Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol 34:519-524, 2004
42. Farshid G, Pradhan M, Kollias J, et al: A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. Breast 13:494-501, 2004